Advertisement
Advertisement
FENC
Fennec Pharmaceuticals Inc. Common Stock
6.77
USDSponsored
-0.26
-3.70%
May 13, 16:00 UTC -4
Closed
Pre-Market
6.78
+0.01
+0.07%
FENC Earnings Reports
Positive Surprise Ratio
FENC beat 15 of 34 last estimates.
44%
Next Report
Today BMO
Date of Next Report
May 14, 2026
Estimate for Q1 26 (Revenue/ EPS)
$14.23M
/$0.00
Implied change from Q4 25 (Revenue/ EPS)
+3.31%
/-100.00%
Implied change from Q1 25 (Revenue/ EPS)
+62.65%
/-100.00%
Fennec Pharmaceuticals Inc. Common Stock earnings per share and revenue
On Mar 24, 2026, FENC reported earnings of -0.10 USD per share (EPS) for Q4 25, missing the estimate of 0.03 USD, resulting in a -380.11% surprise. Revenue reached 13.78 million, compared to an expected 14.27 million, with a -3.48% difference. The market reacted with a -19.19% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 6 analysts forecast an EPS of 0.00 USD, with revenue projected to reach 14.23 million USD, implying an decrease of -100.00% EPS, and increase of 3.31% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were Fennec Pharmaceuticals Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Fennec Pharmaceuticals Inc. Common Stock reported EPS of -$0.10, missing estimates by -380.11%, and revenue of $13.78M, -3.48% below expectations.
How did the market react to Fennec Pharmaceuticals Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -19.19%, changed from $7.45 before the earnings release to $6.02 the day after.
When is Fennec Pharmaceuticals Inc. Common Stock expected to report next?
The next earning report is scheduled for May 14, 2026.
What are the forecasts for Fennec Pharmaceuticals Inc. Common Stock's next earnings report?
Based on 6
analysts, Fennec Pharmaceuticals Inc. Common Stock is expected to report EPS of -- and revenue of $14.23M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement